Wuxi Biologics Inc., of Shanghai, and Amicus Therapeutics Inc., of Cranbury, N.J., inked an exclusive commercial manufacturing partnership covering ATB-200, the alpha-glucosidase stimulator that Amicus is advancing in Pompe disease. Wuxi will enable and support Amicus with global sourcing and will manufacture both the drug substance and product at two sites across its commercial supply network.